What is the success rate of peptide receptor radionuclide therapy?

Peptide receptor radionuclide therapy (PRRT) is an emerging targeted therapy that utilizes radionuclides coupled to peptide analogues to selectively deliver radiation to tumors expressing high levels of somatostatin receptors. PRRT has shown promising response rates and improved progression-free survival in patients with neuroendocrine tumors (NETs).
The success rate of PRRT is dependent on several factors:

• Type of neuroendocrine tumor being treated
  
  
  
  
  • PRRT has higher response rates for gastroenteropancreatic NETs (GEP-NETs) compared to other NET types
  
  


• Extent of disease
  
  
  
  
  • Patients with lower tumor burden and limited metastases tend to have better outcomes
  
  


• Concurrent treatments
  
  
  
  
  • Combining PRRT with other therapies can improve outcomes
  
  


• Molecular imaging to select patients
  
  
  
  
  • Patients undergo somatostatin receptor imaging prior to PRRT to determine if their tumors express adequate receptor levels
  
  

Reported response rates with PRRT:

• GEP-NETs
  
  
  
  
  • Partial response rates: 16-38%
  
  
  • Complete response rates: 2-6%
  
  
  • Disease control rates: 50-100%
  
  


• Bronchial NETs
  
  
  
  
  • Partial response rates: 0-33%
  
  


• Pheochromocytomas/paragangliomas
  
  
  
  
  • Partial response rates: 29-57%
  
  

So response rates with PRRT are variable and dependent on several factors, but partial responses are observed in 16-57% patients, with complete responses in 2-6% patients.

Survival outcomes with PRRT:

• For GEP-NETs, reported progression-free survival is 9 months to >40 months


• 5-year overall survival rates range from 43-63%


• 10-year overall survival rates approach 45% for GEP-NETs

So PRRT can improve progression-free and overall survival for patients with advanced GEP-NETs when applied optimally.

At Balance Hormone Clinic Therapy Clinic, we offer cutting-edge PRRT with lutetium-177 for qualifying patients with advanced NETs. Our world-class endocrinology and nuclear medicine experts carefully evaluate patients to determine if they are likely to benefit from PRRT based on molecular imaging and prognostic factors. We personalize PRRT therapy based on the unique biology of your tumor to provide you the highest chance of response. Contact us today to find out if you may be a candidate for peptide receptor radionuclide therapy!